Cost considerations in the pharmacological prevention and treatment of stroke

Andrei Alexandrov, Liliana T. Smurawska, William Bartle, Paul Oh

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Stroke remains the leading cause of neurological disability and the third leading cause of death worldwide, consuming a large share of total healthcare expenditures. In this review, we discuss the cost effectiveness of stroke prevention for various risk factor-modification programmes and pharmacological interventions with aspirin (acetylsalicylic acid), ticlopidine and warfarin. Cost considerations and potential cost savings resulting from acute treatment are discussed for parenterally administered anticoagulants, such as heparin and nadroparin, and for intravenous thrombolysis with alteplase (recombinant tissue plasminogen activator; r- tPA). Patients with multiple risk factors for stroke require more aggressive prevention strategies which are associated with a greater risk of complications. The rates of complications, particularly intracerebral haemorrhage, should be kept low to achieve cost benefits for warfarin and alteplase. Reduced hospital length of slay is the key factor in the implementation of cost-effective stroke therapies. The analysis of future clinical trials of new stroke therapies should also include economic parameters, such as length of hospital stay and intensity of resource usage, to help guide formulary and therapeutic decisions.

Original languageEnglish (US)
Pages (from-to)408-418
Number of pages11
JournalPharmacoEconomics
Volume11
Issue number5
DOIs
StatePublished - Jan 1 1997
Externally publishedYes

Fingerprint

Stroke
Pharmacology
Costs and Cost Analysis
Tissue Plasminogen Activator
Warfarin
Aspirin
Cost-Benefit Analysis
Length of Stay
Nadroparin
Ticlopidine
Therapeutics
Formularies
Cost Savings
Cerebral Hemorrhage
Health Expenditures
Anticoagulants
Heparin
Cause of Death
Economics
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

Cost considerations in the pharmacological prevention and treatment of stroke. / Alexandrov, Andrei; Smurawska, Liliana T.; Bartle, William; Oh, Paul.

In: PharmacoEconomics, Vol. 11, No. 5, 01.01.1997, p. 408-418.

Research output: Contribution to journalReview article

Alexandrov, Andrei ; Smurawska, Liliana T. ; Bartle, William ; Oh, Paul. / Cost considerations in the pharmacological prevention and treatment of stroke. In: PharmacoEconomics. 1997 ; Vol. 11, No. 5. pp. 408-418.
@article{a2ab0e4f2dee4d8bbe8fe5e22010cd64,
title = "Cost considerations in the pharmacological prevention and treatment of stroke",
abstract = "Stroke remains the leading cause of neurological disability and the third leading cause of death worldwide, consuming a large share of total healthcare expenditures. In this review, we discuss the cost effectiveness of stroke prevention for various risk factor-modification programmes and pharmacological interventions with aspirin (acetylsalicylic acid), ticlopidine and warfarin. Cost considerations and potential cost savings resulting from acute treatment are discussed for parenterally administered anticoagulants, such as heparin and nadroparin, and for intravenous thrombolysis with alteplase (recombinant tissue plasminogen activator; r- tPA). Patients with multiple risk factors for stroke require more aggressive prevention strategies which are associated with a greater risk of complications. The rates of complications, particularly intracerebral haemorrhage, should be kept low to achieve cost benefits for warfarin and alteplase. Reduced hospital length of slay is the key factor in the implementation of cost-effective stroke therapies. The analysis of future clinical trials of new stroke therapies should also include economic parameters, such as length of hospital stay and intensity of resource usage, to help guide formulary and therapeutic decisions.",
author = "Andrei Alexandrov and Smurawska, {Liliana T.} and William Bartle and Paul Oh",
year = "1997",
month = "1",
day = "1",
doi = "10.2165/00019053-199711050-00004",
language = "English (US)",
volume = "11",
pages = "408--418",
journal = "PharmacoEconomics",
issn = "1170-7690",
publisher = "Adis International Ltd",
number = "5",

}

TY - JOUR

T1 - Cost considerations in the pharmacological prevention and treatment of stroke

AU - Alexandrov, Andrei

AU - Smurawska, Liliana T.

AU - Bartle, William

AU - Oh, Paul

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Stroke remains the leading cause of neurological disability and the third leading cause of death worldwide, consuming a large share of total healthcare expenditures. In this review, we discuss the cost effectiveness of stroke prevention for various risk factor-modification programmes and pharmacological interventions with aspirin (acetylsalicylic acid), ticlopidine and warfarin. Cost considerations and potential cost savings resulting from acute treatment are discussed for parenterally administered anticoagulants, such as heparin and nadroparin, and for intravenous thrombolysis with alteplase (recombinant tissue plasminogen activator; r- tPA). Patients with multiple risk factors for stroke require more aggressive prevention strategies which are associated with a greater risk of complications. The rates of complications, particularly intracerebral haemorrhage, should be kept low to achieve cost benefits for warfarin and alteplase. Reduced hospital length of slay is the key factor in the implementation of cost-effective stroke therapies. The analysis of future clinical trials of new stroke therapies should also include economic parameters, such as length of hospital stay and intensity of resource usage, to help guide formulary and therapeutic decisions.

AB - Stroke remains the leading cause of neurological disability and the third leading cause of death worldwide, consuming a large share of total healthcare expenditures. In this review, we discuss the cost effectiveness of stroke prevention for various risk factor-modification programmes and pharmacological interventions with aspirin (acetylsalicylic acid), ticlopidine and warfarin. Cost considerations and potential cost savings resulting from acute treatment are discussed for parenterally administered anticoagulants, such as heparin and nadroparin, and for intravenous thrombolysis with alteplase (recombinant tissue plasminogen activator; r- tPA). Patients with multiple risk factors for stroke require more aggressive prevention strategies which are associated with a greater risk of complications. The rates of complications, particularly intracerebral haemorrhage, should be kept low to achieve cost benefits for warfarin and alteplase. Reduced hospital length of slay is the key factor in the implementation of cost-effective stroke therapies. The analysis of future clinical trials of new stroke therapies should also include economic parameters, such as length of hospital stay and intensity of resource usage, to help guide formulary and therapeutic decisions.

UR - http://www.scopus.com/inward/record.url?scp=0030964949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030964949&partnerID=8YFLogxK

U2 - 10.2165/00019053-199711050-00004

DO - 10.2165/00019053-199711050-00004

M3 - Review article

VL - 11

SP - 408

EP - 418

JO - PharmacoEconomics

JF - PharmacoEconomics

SN - 1170-7690

IS - 5

ER -